1.Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma.
Soo Jin BAE ; Christine KANG ; Ki Woong SUNG ; Hee Won CHUEH ; Meong Hi SON ; Soo Hyun LEE ; Keon Hee YOO ; Hong Hoe KOO
Journal of Korean Medical Science 2012;27(4):363-369
Multiple RBC transfusions inevitably lead to a state of iron overload before and after high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT). Nonetheless, iron status during post-SCT follow-up remains unknown. Therefore, we investigated post-SCT ferritin levels, factors contributing to its sustained levels, and organ functions affected by iron overload in 49 children with high-risk neuroblastoma who underwent tandem HDCT/autoSCT. Although serum ferritin levels gradually decreased during post-SCT follow-up, 47.7% of the patients maintained ferritin levels above 1,000 ng/mL at 1 yr after the second HDCT/autoSCT. These patients had higher serum creatinine (0.62 vs 0.47 mg/mL, P = 0.007) than their counterparts (< 1,000 ng/mL). Post-SCT transfusion amount corresponded to increased ferritin levels at 1 yr after the second HDCT/autoSCT (P < 0.001). A lower CD34+ cell count was associated with a greater need of RBC transfusion, which in turn led to a higher serum ferritin level at 1 yr after HDCT/autoSCT. The number of CD34+ cells transplanted was an independent factor for ferritin levels at 1 yr after the second HDCT/autoSCT (P = 0.019). Consequently, CD34+ cells should be transplanted as many as possible to prevent the sustained iron overload after tandem HDCT/autoSCT and consequent adverse effects.
Antigens, CD34/metabolism
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Benzoic Acids/therapeutic use
;
Blood Transfusion/*adverse effects
;
Child
;
Child, Preschool
;
Creatinine/blood
;
Ferritins/blood
;
Follow-Up Studies
;
Humans
;
Infant
;
Iron Chelating Agents/therapeutic use
;
Iron Overload/*etiology
;
Neuroblastoma/drug therapy/*therapy
;
Retrospective Studies
;
Risk Factors
;
*Stem Cell Transplantation
;
Transplantation, Autologous
;
Triazoles/therapeutic use
2.Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma.
Soo Jin BAE ; Christine KANG ; Ki Woong SUNG ; Hee Won CHUEH ; Meong Hi SON ; Soo Hyun LEE ; Keon Hee YOO ; Hong Hoe KOO
Journal of Korean Medical Science 2012;27(4):363-369
Multiple RBC transfusions inevitably lead to a state of iron overload before and after high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT). Nonetheless, iron status during post-SCT follow-up remains unknown. Therefore, we investigated post-SCT ferritin levels, factors contributing to its sustained levels, and organ functions affected by iron overload in 49 children with high-risk neuroblastoma who underwent tandem HDCT/autoSCT. Although serum ferritin levels gradually decreased during post-SCT follow-up, 47.7% of the patients maintained ferritin levels above 1,000 ng/mL at 1 yr after the second HDCT/autoSCT. These patients had higher serum creatinine (0.62 vs 0.47 mg/mL, P = 0.007) than their counterparts (< 1,000 ng/mL). Post-SCT transfusion amount corresponded to increased ferritin levels at 1 yr after the second HDCT/autoSCT (P < 0.001). A lower CD34+ cell count was associated with a greater need of RBC transfusion, which in turn led to a higher serum ferritin level at 1 yr after HDCT/autoSCT. The number of CD34+ cells transplanted was an independent factor for ferritin levels at 1 yr after the second HDCT/autoSCT (P = 0.019). Consequently, CD34+ cells should be transplanted as many as possible to prevent the sustained iron overload after tandem HDCT/autoSCT and consequent adverse effects.
Antigens, CD34/metabolism
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Benzoic Acids/therapeutic use
;
Blood Transfusion/*adverse effects
;
Child
;
Child, Preschool
;
Creatinine/blood
;
Ferritins/blood
;
Follow-Up Studies
;
Humans
;
Infant
;
Iron Chelating Agents/therapeutic use
;
Iron Overload/*etiology
;
Neuroblastoma/drug therapy/*therapy
;
Retrospective Studies
;
Risk Factors
;
*Stem Cell Transplantation
;
Transplantation, Autologous
;
Triazoles/therapeutic use